Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Identify situations where TRI provides a fuller view of performance than a price index, especially when dividends and compounding matter to total returns.
26,715 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Fundstrat’s Granny Shots ETF outperforms the S&P 500 through mid-2026, fueling debate as Tom Lee raises the odds of a...
A Georgia-based accessory maker will pay $1.75 million in restitution to Buffalo shooting victims’ families and halt ...
Two SUI spot ETFs kicked off trading in the U.S. on Feb. 18, 2026, yet debut volume was muted. The scene highlights t...
A director sold 45,000 LUMN shares, triggering questions about Lumen Technologies stock sell signals. This article br...
A lithium-extraction startup says its new method triples recovery while shortening timelines, accelerating toward com...
Costco is set to report Q2 FY2026 results after the bell, with analysts projecting a solid beat on earnings and reven...
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Energy stocks are rallying as demand rebounds and cash flow improves. This piece spotlights the best energy stocks to...
Strategy and Bitmine Immersion Technologies fell about 6% as crypto sentiment soured, highlighting the volatility and...
A Seattle-area clinic is adopting a stark, device-free recovery model for tech addiction, with detox programs lasting...
Policy watchers say a White House-backed regulatory milestone could open crypto and private equity to trillions in re...